Bukwang Pharmaceutical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 47,824.72 million compared to KRW 40,349.84 million a year ago. Net income was KRW 657.42 million compared to net loss of KRW 6,156.85 million a year ago. Basic earnings per share from continuing operations was KRW 10 compared to basic loss per share from continuing operations of KRW 90.9091 a year ago. Diluted earnings per share from continuing operations was KRW 10 compared to diluted loss per share from continuing operations of KRW 90.9091 a year ago. Basic earnings per share was KRW 10 compared to basic loss per share of KRW 100 a year ago.
For the nine months, sales was KRW 128,546.34 million compared to KRW 120,194.16 million a year ago. Net loss was KRW 2,825.56 million compared to KRW 5,648.59 million a year ago. Basic loss per share from continuing operations was KRW 41 compared to KRW 81.8182 a year ago. Diluted loss per share from continuing operations was KRW 41 compared to KRW 81.8182 a year ago. Basic loss per share was KRW 41 compared to KRW 90 a year ago.